Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals
AssigneeLudwig Institute for Cancer Research
InventorsThierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethé
Life of this patent
Estimating the term…
Abstract
The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
Claims3
A method for screening an HLA-B44 positive patient for possible presence of melanoma cells which present complexes of HLA-B44 and a peptide derived from tyrosinase, comprising contacting a sample of abnormal cells taken from said HLA-B44 positive patient with a cytolytic T cell specific for a complex of HLA-B44 and a peptide derived from tyrosinase, and determining (i) release of TNF from said cytolytic T cells or (ii) lysis of said HLA-B44 positive cells in said patient as a determination of possible melanoma in said patient.
A method for screening an HLA-B44 positive patient for possible presence of melanoma cells, which present complexes of HLA-B44 and a peptide derived from tyrosinase, comprising contacting a sample of abnormal cells taken from said HLA-B44 positive patient with a cytolytic T cell specific for a complex of HLA-B44 and a peptide derived from tyrosinase, and determining lysis of said HLA-B44 positive cells in said sample of abnormal cells from said patient, as determination of possible melanoma in said patient.
Dependencies are inferred from the claim text.